LUND, Sweden, May 12, 2020 /PRNewswire/ -- Immunovia invites
you to a teleconference (in English) for all stakeholders and media
on Wednesday, May 13, 2020 at
16:30 CET. Mats Grahn, CEO will present an update on the
company's COVID-19 response as well as an update on the activities
in preparation for the launch of IMMray™ PanCan-d and the
prospective studies followed by a Q&A session.
Participants will need to pre-register for the call via the
following link: Register Here
Once pre-registered, each participant will then receive a
personal user code to access the live call.
For the live call, please call in a few minutes in advance. To
attend, please dial-in at one of the numbers below and provide the
conference code 2514192 to the operator as well as your user
code obtained from pre-registration:
Conference Dial in numbers:
Sweden: +46-(0)-8-5051-0086
United States:
+1-646-843-4609
Austria: +43-(0)-1928-4054
Denmark: +45-3272-9274
Finland: +358-9-2319-5436
France: +33-(0)-4-2684-0314
Germany:
+49-(0)-511-9361-2555
Netherlands:
+31-(0)-20-7948428
Norway: +47-2-156-3319
Spain: +34-91-787-0778
UK (Standard International Access): +44-(0)-20-3003-2701
Conference Code: 2514192
User Code: obtained from pre-registration (Register
Here)
Immunovia
Webcast: https://channel.royalcast.com/webcast/immunovia/20200513_1/
For more information, please contact:
Julie Silber, Director of
Investor Relations,
Immunovia Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
There will be an MP3-file available at Immunovia's webpage under
Investors/Audio-Gallery
(https://immunovia.com/investors/audio-gallery/) for those who want
to listen to the telephone conference afterwards. The file will be
available within two hours after the conference has ended.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently entering the final validation for sales start Q3
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
CONTACT:
Immunovia AB
Medicon Village Scheelevägen 2 SE-223 81 Lund
+46 46 275 60 00
http://www.immunovia.com
info@immunovia.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/invitation-to-immunovia-s-update--3-on-covid-19-company-response,c3110034
The following files are available for download:
https://mb.cision.com/Main/13121/3110034/1246532.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/invitation-to-immunovias-update-3-on-covid-19-company-response-301057855.html
SOURCE Immunovia AB